A population-based screening program provides insights into the characteristics and behaviors of individuals who self-refer for gambling disorder.

Introduction: Since only around 10% of people with gambling disorder (GD) seek professional treatment or attend self-help groups, multiple strategies are needed to improve this rate. The proposal of the Behavioral Addictions Centre 'Adcom' (Madrid, Spain) is one of these strategies, a pioneering and innovative program aimed at the general population to identify people with addictions such as GD, in an attempt tp offer them appropriate evidence-based treatments.

Materials And Methods: We analyzed information obtained from the first 305 adults who voluntarily sought attention at Adcom for self-referred gambling, and conducted a descriptive, cross-sectional and observational study of this population.

Exploring the Impact of Schizophrenia and Its Pharmacological Treatment on Health-Related Quality of Life and Treatment Preferences.

Purpose: Pharmacological treatments play an important role in managing symptoms of schizophrenia but can also be associated with side effects. The aim of this study was to understand the impact of schizophrenia and its pharmacological treatment on patients' health-related quality of life (HRQoL) and to explore patient preferences around treatment benefits and side effects.

Patients And Methods: This study employed a mixed methods approach with two stages of recruitment of adult patients in Spain.

The need to prioritize "insomnia disorder" in public health agendas: "a wakeup call" position paper from European and Canadian experts in sleep and mental health.

Objective: Insomnia Disorder is a chronic mental disorder with significant impact on the population across Europe and Canada. While some countries reimburse evidence-based treatments, others fail to recognize insomnia as a chronic condition and do not provide the resources to ensure consistent care for those affected. This document serves as a position paper from sleep and mental health experts across Europe, Switzerland the UK, and Canada, emphasizing the critical need for public health systems to recognize chronic insomnia as a disorder in order to enhance support for patients.

Baseline Clinical Characterization of Participants in the Accelerating Medicines Partnership Schizophrenia Program.

Background: This paper focuses on the baseline clinical characterization of the participants in the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program. The AMP SCZ program is designed to investigate a wide array of clinical variables and biomarkers in a total of 2040 clinical high-risk (CHR) participants and 652 community control (CC) participants.

Methods: The dataset analyzed includes 1642 individuals at clinical high risk for psychosis and 519 CCs.

Sample Ascertainment and Recruitment Sources in the Accelerating Medicines Partnership Schizophrenia Program.

Background: This paper presents the recruitment sources of clinical high-risk (CHR) and community controls (CC) from the Accelerating Medicines Partnership Schizophrenia (AMP SCZ) program, which aims to study various clinical variables and biomarkers in 2040 CHR and 652 CC participants.

Methods: A total of 1640 CHR and 514 CC had recruitment source data. The Positive Symptoms and Diagnostic Criteria for the Comprehensive Assessment of At-Risk Mental States Harmonized with the SIPS was utilized to assess CHR criteria and severity of attenuated psychotic symptoms (APSs), and the Global Functioning: Social Scale was used for social functioning.

Autoantibodies against myelin oligodendrocyte glycoprotein in a subgroup of patients with psychotic symptoms.

The presence of autoantibodies against myelin oligodendrocyte glycoprotein (MOG) is a hallmark of MOG antibody-associated disease (MOGAD), a recently defined demyelinating disease entity presenting with core clinical features of optic neuritis, myelitis, and acute disseminated encephalomyelitis. Although MOG antibodies have also been described in a small number of patients with other conditions, including mental disorders, their prevalence and clinical specificity in patients with isolated psychotic symptoms remain unclear. Here, we screened sera from 262 patients with at least one psychotic episode and 166 control subjects for the presence of MOG antibodies of the immunoglobulin G (IgG) isotype with a live cell-based assay.

Schizophrenia treatment preferences of psychiatrists versus guidelines: A European perspective.

Background: We aimed to identify therapeutic approaches for managing schizophrenia in different phases and clinical situations - the prodromal phase, first-episode psychosis, cognitive and negative symptoms, pregnancy, treatment resistance, and antipsychotic-induced metabolic side effects - while assessing clinicians' adherence to guidelines.

Methods: A cross-sectional online survey was conducted in 2023 as part of the Ambassador project among psychiatrists and trainees from 35 European countries, based on a questionnaire that included six clinical vignettes (cases A-F). Additionally, a review of multiple guidelines/guidance papers was performed.

The Mental Health Clinical Liaison Programme for Schools: developing a new approach in Child and Adolescent Mental Healthcare in Spain.

Mental health issues among children and adolescents have increased, especially after the COVID-19 pandemic. Despite awareness, less than half get needed care, leading to long-term consequences. The World Health Organization calls for integrated, preventive community interventions.

Transcriptomic decoding of surface-based imaging phenotypes and its application to pharmacotranscriptomics.

Imaging transcriptomics has become a power tool for linking imaging-derived phenotypes (IDPs) to genomic mechanisms. Yet, its potential for guiding CNS drug discovery remains underexplored. Here, utilizing spatially-dense representations of the human brain transcriptome, we present an analytical framework for the transcriptomic decoding of high-resolution surface-based neuroimaging patterns, and for linking IDPs to the transcriptomic landscape of complex neurotransmission systems in vivo.

Human development, inequality, and their associations with brain structure across 29 countries.

Background: The macro-social and environmental conditions in which people live, such as the level of a country's development or inequality, are associated with brain-related disorders. However, the relationship between these systemic environmental factors and the brain remains unclear. We aimed to determine the association between the level of development and inequality of a country and the brain structure of healthy adults.

Extrapyramidal symptoms as early clinical predictors in first-episode schizophrenia and schizophreniform disorder: findings from the OPTiMiSE trial.

Extrapyramidal symptoms (EPS) may occur as a primary feature in patients with first-episode psychosis with no or brief exposure to antipsychotics (AP). We aimed to analyse the prevalence of EPS in naïve and quasi-naïve first episode schizophrenia spectrum disorders (FES), their demographic and clinical correlates at baseline, and their association with clinical outcomes during follow-up. We analysed data from the OPTiMiSE trial, Phase 1 (n = 481 participants with FES, aged 18-40).

Linking prolonged childhood and adolescent loneliness to schizophrenia spectrum disorders: results from EU-GEI study.

Background: Prolonged childhood and adolescent loneliness (CAL) is linked to various adverse mental health outcomes, yet its impact on schizophrenia spectrum disorders (SSD) has been understudied. While loneliness is associated with psychosis and worsens symptoms in SSD, few studies have explored the long-term effects of early loneliness on SSD risk. Understanding how CAL interacts with genetic liability to schizophrenia is essential for identification of high-risk individuals.

Cerebral cortical alterations in adolescent early-onset psychosis: a surface-based morphometry mega-analysis.

Cortical brain morphology in early-onset psychosis (EOP; age of onset < 19 years) is poorly understood, partly due to recruitment constraints linked to its low incidence. We pooled T1-weighted magnetic resonance imaging (MRI) data from 387 adolescents with EOP (mean age=16.1±1.

The electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures.

Individuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments. Moreover, given risks of antipsychotic drugs, safer effective medications for CHR individuals are needed. The Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ) Program was launched to address this need.

Digital health technologies in the accelerating medicines Partnership® Schizophrenia Program.

Although meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level. Digital phenotyping offers a novel approach to explore the nature of CHR and may help to improve personalized risk prediction. Specifically, digital data enable detailed mapping of experiences, moods and behaviors during longer periods of time (e.

Heterogeneity of morphometric similarity networks in health and schizophrenia.

Reduced structural network connectivity is proposed as a biomarker for chronic schizophrenia. This study assessed regional morphometric similarity as an indicator of cortical inter-regional connectivity, employing longitudinal normative modeling to evaluate whether decreases are consistent across individuals with schizophrenia. Normative models were trained and validated using data from healthy controls (n = 4310).

Mental health status of the European population and its determinants: A cross-national comparison study.

Background: This study aimed to provide an up-to-date cross-national comparison of the European population mental health (MH) and its

Methods: For the European Union (EU) 27 countries and the UK 6 Key Performance Indicators (KPIs) in (e.g., prevalence of mental disorders) and 19 KPIs in individual (e.

Comparison between accelerated and standard or sham rTMS in the treatment of depression: A systematic review.

Major depressive disorder (MDD) represents a major global health challenge, with a significant proportion of patients being resistant to drug treatment (TRD). Repetitive transcranial magnetic stimulation (rTMS) has shown promise in the treatment of MDD/TRD, with a single stimulation session per day for five days per week over several weeks (the "standard" protocol). The two main paradigms used are high-frequency rTMS and intermittent theta burst stimulation (iTBS) delivered to the left dorsolateral prefrontal cortex (DLPFC).

Assessment of functional recovery in patients with schizophrenia, with a focus on early-phase disease: results from a Delphi consensus and narrative review.

Background: Treatment of schizophrenia has traditionally aimed for symptomatic remission without addressing many daily problems patients face. Although no standard definition of functional recovery in patients with first-episode psychosis (FEP) and early-phase (EP) schizophrenia exists in the literature, most clinicians consider it a useful concept in daily practice. We conducted a Delphi panel to develop expert consensus on assessing functional recovery in FEP and EP schizophrenia patients and defining its domains, which we compared with currently available patient- and clinician-reported outcome measures (PROMs, CROMs).

PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample.

Predicting outcomes in individuals at clinical high risk (CHR) of developing psychosis remains challenging using clinical metrics alone. The PSYSCAN project aimed to enhance predictive value by integrating data across clinical, environmental, neuroimaging, cognitive, and peripheral blood biomarkers. PSYSCAN employed a naturalistic, prospective design across 12 sites (Europe, Australia, Asia, Americas).

Responsiveness of European countries to the population mental health needs: A cross-national comparison study.

Background: This study aimed to cross-compare European countries' responsiveness to their populations' mental health (MH) needs.

Methods: For the EU-27 countries and the United Kingdom, the 2023 Headway Initiative collected data on 15 key performance indicators (KPIs) in responsiveness in healthcare, including workforce, facilities, quality of care, and MH expenditure, and 14 KPIs in responsiveness in workplaces, schools, and society. Bivariate correlations between Headway-transformed KPI scores, which were standardised in a 1-10 Likert Scale (1: worst performance; 10: best performance), tested for putative associations.

Do biological alterations precede the onset of psychosis? A systematic review and meta-analysis of immune, cardiometabolic, prolactin and HPA axis alterations in clinical high-risk for psychosis.

First episode psychosis (FEP) individuals show biological abnormalities preceding antipsychotic treatment. However, it remains unclear whether such alterations are also present before the onset of psychosis. We aim to provide estimates of standardized mean differences for immune, cardiometabolic, prolactin, and HPA axis parameters in individuals at clinical high-risk for psychosis (CHR-P) compared to healthy controls (HC) and FEP individuals, and between CHR-P transitioning to psychosis (CHR-T) compared non-transitioning (CHR-NT).

Bridging Science and Hope: integrating and Communicating Lived experience in Accelerating Medicines Partnership® Schizophrenia Program.

The Accelerating Medicines Partnership Schizophrenia (AMP® SCZ) program integrates lived experience into psychosis research, leveraging over three decades of foundational studies to improve research quality, promote community engagement, and ensure ethical implementation of precision psychiatry. Lived experience is embedded in the program’s governance, shaping study protocols, recruitment strategies, and digital tools such as the mindLAMP platform. Study sites also integrate lived experience through youth advisory boards, peer support specialists, and advisory committees, ensuring diverse perspectives inform research design and implementation.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms.

Background And Hypotheses: Negative symptoms of schizophrenia (NSS) carry a substantial burden, and there are no treatments currently approved for NSS. The efficacy of pimavanserin, a selective 5-HT2A inverse agonist and antagonist, in treating NSS was assessed.

Study Design: ADVANCE-2 was a phase 3, randomized, double-blind, placebo-controlled study of pimavanserin in patients with schizophrenia and predominantly negative symptoms.